Advertisement

Medical Oncology

, Volume 27, Issue 2, pp 291–295 | Cite as

Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy

A pooled-data analysis
  • Angelo ZulloEmail author
  • Cesare Hassan
  • Alessandro Andriani
  • Francesca Cristofari
  • Chiara Bassanelli
  • Gian Paolo Spinelli
  • Silverio Tomao
  • Sergio Morini
Original Paper

Abstract

The most favourable therapeutic strategy for gastric MALT-lymphoma not responding to Helicobacter pylori eradication still remains unclear, neither official guidelines nor randomised studies being available. We therefore performed a systematic review of the literature to evaluate the efficacy of different therapeutic approaches in these patients. Data regarding 315 patients were valuable, and lymphoma remission following the first therapeutic attempt was achieved in 90.1% cases. The most used therapy was radiotherapy (112 patients), followed by surgery (80 patients) and chemotherapy (68 patients), whilst a combination therapy was less frequent. Radiotherapy achieved a higher remission rate as compared to chemotherapy (97.3 vs. 85.3%; P = 0.007), being similar to surgery (97.3 vs. 92.5%; P = 0.2). No difference emerged when comparing lymphoma remission rate achieved by a single therapy with that of combined treatments (89.6 vs. 96.4%; P = 0.6). This is the first pooled-data analysis assessing the efficacy of different oncologic therapeutic approaches to treat gastric MALT-lymphoma unresponsive to H. pylori eradication. Radiotherapy seems to be the most suitable treatment in these patients.

Keywords

Gastric MALT-lymphoma Oncologic therapy Lymphoma remission Helicobacter pylori 

References

  1. 1.
    Cavalli F, et al. MALT lymphomas. Hematology Am Soc Hematol Educ Program. 2001;241–58. doi: 10.1182/asheducation-2001.1.241.
  2. 2.
    Stolte M, et al. Helicobacter pylori and gastric MALT lymphoma. Gut. 2002;50(Suppl 3):19–24. doi: 10.1136/gut.50.suppl_3.iii19.Google Scholar
  3. 3.
    Andriani A, et al. Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Aliment Pharmacol Ther. 2006;23:721–6. doi: 10.1111/j.1365-2036.2006.02826.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Malfertheiner P, et al. Current concepts in the management of Helicobacter pylori infection—the Maastricht III consensus report. Gut. 2007;56:772–81. doi: 10.1136/gut.2006.101634.CrossRefPubMedGoogle Scholar
  5. 5.
    Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1–18. doi: 10.1111/j.1572-0241.2007.01393.x.CrossRefGoogle Scholar
  6. 6.
    Fujioka T, et al. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J Gastroenterol. 2007;42(Suppl 17):3–6. doi: 10.1007/s00535-006-1938-3.CrossRefPubMedGoogle Scholar
  7. 7.
    Caselli M, et al. Cervia II Working Group Report 2006: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39:782–9. doi: 10.1016/j.dld.2007.05.016.CrossRefPubMedGoogle Scholar
  8. 8.
    Zinzani PL. Thoughts on the eradication of Helicobacter pylori infection in localized gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2006;47:2013–4. doi: 10.1080/10428190600774873.CrossRefPubMedGoogle Scholar
  9. 9.
    Andriani A, et al. Management and long-term follow up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicenter study. Dig Liver Dis. 2008 [Epub ahead of print].Google Scholar
  10. 10.
    Savio A, et al. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol’s adequacy. Recent Results Cancer Res. 2000;156:116–24.PubMedGoogle Scholar
  11. 11.
    Papa A, et al. Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma: a long-term follow-up study. J Clin Gastroenterol. 2000;31:169–71. doi: 10.1097/00004836-200009000-00018.CrossRefPubMedGoogle Scholar
  12. 12.
    Caletti G, et al. The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. Aliment Pharmacol Ther. 2002;16:1715–22. doi: 10.1046/j.1365-2036.2002.01334.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Levy M, et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol. 2002;97:292–7. doi: 10.1111/j.1572-0241.2002.05460.x.CrossRefPubMedGoogle Scholar
  14. 14.
    Nakamura S, et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer. 2005;104:532–40. doi: 10.1002/cncr.21152.CrossRefPubMedGoogle Scholar
  15. 15.
    Akamatsu T, et al. Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter. 2006;11:86–95. doi: 10.1111/j.1523-5378.2006.00382.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Steinbach G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999;131:88–95.PubMedGoogle Scholar
  17. 17.
    Sugimoto M, et al. Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern Med. 2006;45:405–9. doi: 10.2169/internalmedicine.45.1473.CrossRefPubMedGoogle Scholar
  18. 18.
    Raderer M, et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol. 2001;12:937–9. doi: 10.1023/A:1011122904602.CrossRefPubMedGoogle Scholar
  19. 19.
    Terai S, et al. Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas after Helicobacter pylori eradication therapy. Tohoku J Exp Med. 2008;214:79–87. doi: 10.1620/tjem.214.79.CrossRefPubMedGoogle Scholar
  20. 20.
    Begum S, et al. Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. J Med Invest. 2000;47:36–46.PubMedGoogle Scholar
  21. 21.
    Agresta F, et al. Gastric MALT lymphomas: the value of an endoscopic follow-up evaluation. Surg Endosc. 2000;14:1153–5. doi: 10.1007/s004640000239.CrossRefPubMedGoogle Scholar
  22. 22.
    El-Zahabi LM, et al. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest Endosc. 2007;65:89–96. doi: 10.1016/j.gie.2006.05.009.CrossRefPubMedGoogle Scholar
  23. 23.
    de Jong D, et al. Histological and immunological parameters to predict treatment outcome of Helicobacter pylori eradication in low-grade gastric MALT lymphoma. J Pathol. 2001;193:318–24. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH811>3.0.CO;2-Z.CrossRefPubMedGoogle Scholar
  24. 24.
    Kawahara Y, et al. HLA-DQA1*0103-DQB1*0601 haplotype and Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2005;3:865–8. doi: 10.1016/S1542-3565(05)00185-0.CrossRefPubMedGoogle Scholar
  25. 25.
    Matsushima Y, et al. Immunological and molecular analysis of B lymphocytes in low-grade MALT lymphoma of the stomach Are there any useful markers for predicting outcome after Helicobacter pylori eradication? J Gastroenterol. 2002;37:428–33. doi: 10.1007/s005350200062.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim YS, et al. Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation. J Gastroenterol. 2002;37:17–22. doi: 10.1007/s535-002-8127-8.CrossRefPubMedGoogle Scholar
  27. 27.
    Sheu BS, et al. Clinical application of 20 MHZ endosonography and anti-Helicobacter pylori immunoblots to predict regression of low-grade gastric Maltoma by H. pylori eradication. Helicobacter. 2003;8:36–45. doi: 10.1046/j.1523-5378.2003.00122.x.CrossRefPubMedGoogle Scholar
  28. 28.
    Ohashi S, et al. Gastrin and Helicobacter pylori in low-grade MALT lymphoma patients. Scand J Gastroenterol. 2002;37:279–86. doi: 10.1080/003655202317284174.CrossRefPubMedGoogle Scholar
  29. 29.
    Wündisch T, et al. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: results of a 196-patient series. Leuk Lymphoma. 2006;47:2110–4. doi: 10.1080/10428190600783536.CrossRefPubMedGoogle Scholar
  30. 30.
    Montalban C, et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. Ann Oncol. 2005;16:1539–44. doi: 10.1093/annonc/mdi277.CrossRefPubMedGoogle Scholar
  31. 31.
    Dong G, et al. BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. Int J Hematol. 2008;88:516–23. doi: 10.1007/s12185-008-0187-z.CrossRefPubMedGoogle Scholar
  32. 32.
    Noy A, et al. Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. J Clin Oncol. 2005;23:3768–72. doi: 10.1200/JCO.2005.10.018.CrossRefPubMedGoogle Scholar
  33. 33.
    Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916–21.PubMedGoogle Scholar
  34. 34.
    Jager G, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20:3872–7. doi: 10.1200/JCO.2002.05.117.CrossRefPubMedGoogle Scholar
  35. 35.
    Martinelli G, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not elegible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979–83. doi: 10.1200/JCO.2005.08.128.CrossRefPubMedGoogle Scholar
  36. 36.
    de Mascarel A, et al. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch. 2005;446:219–24. doi: 10.1007/s00428-005-1217-3.CrossRefPubMedGoogle Scholar
  37. 37.
    Lee SK, et al. Low grade gastric mucosa associated lymphoid tissue lymphoma: treatment strategies based on 10 year follow-up. World J Gastroenterol. 2004;10:223–6.PubMedGoogle Scholar
  38. 38.
    Wündisch T, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23:8018–24. doi: 10.1200/JCO.2005.02.3903.CrossRefPubMedGoogle Scholar
  39. 39.
    Hong SS, et al. A prospective analysis of low-grade gastric MALT lymphoma after Helicobacter pylori eradication. Helicobacter. 2006;11:569–73. doi: 10.1111/j.1523-5378.2006.00460.x.CrossRefPubMedGoogle Scholar
  40. 40.
    Fischbach W, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53:34–7. doi: 10.1136/gut.53.1.34.CrossRefPubMedGoogle Scholar
  41. 41.
    Wenston AP, et al. Prospective long-term endoscopic and histologic follow-up of gastric lymphoproliferative disease of early stage I.E low-gared B-cell mucosa-associated lymphoid tissue type following Helicobacter pylori eradication treatment. Int J Oncol. 1999;15:899–907.Google Scholar
  42. 42.
    Ishii E, et al. Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 60 is closely associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. Clin Diagn Lab Immunol. 2001;8:1056–9. doi: 10.1128/CDLI.8.6.1056-1059.2001.PubMedGoogle Scholar
  43. 43.
    Bertoni F, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood. 2002;99:2541–4. doi: 10.1182/blood.V99.7.2541.CrossRefPubMedGoogle Scholar
  44. 44.
    Kim JS, et al. Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer. 2007;96:1324–8.PubMedGoogle Scholar
  45. 45.
    Takenaka R, et al. Serum antibodies to Helicobacter pylori and its heat-shock protein 60 correlate with the response of gastric mucosa-associated lymphoid tissue lymphoma to eradication of H. pylori. Helicobacter. 2004;9:194–200. doi: 10.1111/j.1083-4389.2004.00225.x.CrossRefPubMedGoogle Scholar
  46. 46.
    Kanda M, et al. Changes in patterns of immunoglobulin heavy chain gene rearrangement and MIB-1 staining before and after eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2002;42:639–47. doi: 10.3109/10428190109099324.CrossRefGoogle Scholar
  47. 47.
    Ono S, et al. Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment. Gastrointest Endosc. 2008;68:624–31. doi: 10.1016/j.gie.2008.02.066.CrossRefPubMedGoogle Scholar
  48. 48.
    Hiyama T, et al. Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability. Int J Oncol. 2001;18:1207–12.PubMedGoogle Scholar
  49. 49.
    de mascarel A, et al. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch. 2005;446:219–24.CrossRefPubMedGoogle Scholar
  50. 50.
    Raderer M, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006;55:616–8. doi: 10.1136/gut.2005.083022.CrossRefPubMedGoogle Scholar
  51. 51.
    Zucca E, Dreyling M. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):70–1.Google Scholar
  52. 52.
    Fischbach W, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut. 2007;56:1685–7. doi: 10.1136/gut.2006.096420.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Angelo Zullo
    • 1
    Email author
  • Cesare Hassan
    • 1
  • Alessandro Andriani
    • 2
  • Francesca Cristofari
    • 1
  • Chiara Bassanelli
    • 1
  • Gian Paolo Spinelli
    • 3
  • Silverio Tomao
    • 3
  • Sergio Morini
    • 1
  1. 1.Gastroenterology and Digestive Endoscopy“Nuovo Regina Margherita” HospitalRomeItaly
  2. 2.Haematology“Nuovo Regina Margherita” HospitalRomeItaly
  3. 3.“Regina Elena” National Cancer InstituteRomeItaly

Personalised recommendations